miR-17-5p-CXCL14 axis related transcriptome profile and clinical outcome in diffuse gliomas

References

• Dahlrot RH, Hermansen SK, Hansen S, Kristensen BW. What is the clinical value of cancer stem cell markers in gliomas? Int J Clin Exp Pathol. 2013;6:334–348.
   PubMed Web of Science ®Google Scholar
• Zeng AL, Yan W, Liu YW, Wang Z, Hu Q, Nie E, Zhou X, Li R, Wang X-F, Jiang T, et al. Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma. Oncogene. 2017. doi:10.1038/onc.2017.134.
   Web of Science ®Google Scholar
• Zeng A, Hu Q, Liu Y, Wang Z, Cui X, Li R, Yan W, You Y. IDH1/2 mutation status combined with Ki-67 labeling index defines distinct prognostic groups in glioma. Oncotarget.2015;6:30232–30238. doi:10.18632/oncotarget.4920.
   PubMedGoogle Scholar
• Vartanian A, Singh SK, Agnihotri S, Jalali S, Burrell K, Aldape KD, Zadeh G. GBM’s multifaceted landscape: highlighting regional and microenvironmental heterogeneity. Neuro Oncol.2014;16:1167–1175. doi:10.1093/neuonc/nou035.
   PubMed Web of Science ®Google Scholar
• Li S, Zeng A, Hu Q, Yan W, Liu Y, You Y. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas. Neuro Oncol. 2017;19:55–65. doi:10.1093/neuonc/now129.
   Web of Science ®Google Scholar
• Hart MG, Garside R, Rogers G, Stein K, Grant R. Temozolomide for high grade glioma. The Cochrane database of systematic reviews. 2013;(4):Cd007415.
   Google Scholar
• Zhang C, Cheng W, Ren X, Wang Z, Liu X, Li G, Han S, Jiang T, Wu A. Tumor Purity as an Underlying Key Factor in Glioma. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research.2017;23:6279–6291. doi:10.1158/1078-0432.CCR-16-2598.
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun.2013;4:2612. doi:10.1038/ncomms3612.
   PubMed Web of Science ®Google Scholar
• Hossain A, Gumin J, Gao F, Figueroa J, Shinojima N, Takezaki T, Priebe W, Villarreal D, Kang SG, Joyce C, et al. Mesenchymal Stem Cells Isolated From Human Gliomas Increase Proliferation and Maintain Stemness of Glioma Stem Cells Through the IL-6/gp130/STAT3 Pathway. Stem Cells.2015;33:2400–2415. doi:10.1002/stem.2053.
   PubMed Web of Science ®Google Scholar
• Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci. 2016;19:20–27. doi:10.1038/nn.4185.
   PubMed Web of Science ®Google Scholar
• Rolle K. miRNA Multiplayers in glioma. From Bench to Bedside. Acta Biochimica Polonica. 2015;62:353–365. doi:10.18388/abp.2015_1072.
   PubMed Web of Science ®Google Scholar
• Shea A, Harish V, Afzal Z, Chijioke J, Kedir H, Dusmatova S, Roy A, Ramalinga M, Harris B, Blancato J, et al. MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics. Cancer Med.2016;5:1917–1946. doi:10.1002/cam4.775.
   PubMed Web of Science ®Google Scholar
• Zeng A, Yin J, Li Y, Li R, Wang Z, Zhou X, Xin J, Feng S, Wei Y, Yongping Y. miR-129-5p targets Wnt5a to block PKC/ERK/NF-kappaB and JNK pathways in glioblastoma. Cell Death Dis.2018;9:394. doi:10.1038/s41419-018-0343-1.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264. doi:10.1038/nrc3239.
   PubMed Web of Science ®Google Scholar
• Shi L, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol. 2013;6:74. doi:10.1186/1756-8722-6-74.
   PubMed Web of Science ®Google Scholar
• Chow MT, Luster AD. Chemokines in cancer. Cancer Immunol Res. 2014;2:1125–1131. doi:10.1158/2326-6066.CIR-14-0160.
   PubMed Web of Science ®Google Scholar
• Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17:559–572. doi:10.1038/nri.2017.49.
   PubMed Web of Science ®Google Scholar
• Hara T, Tanegashima K. CXCL14 antagonizes the CXCL12-CXCR4 signaling axis. Biomol Concepts. 2014;5:167–173. doi:10.1515/bmc-2014-0007.
   PubMedGoogle Scholar
• Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature.2001;410:50–56. doi:10.1038/35065016.
   PubMed Web of Science ®Google Scholar
• Bertolini F, Dell’Agnola C, Mancuso P, Rabascio C, Burlini A, Monestiroli S, Gobbi A, Pruneri G, Martinelli G. CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin’s lymphoma. Cancer Res. 2002;62:3106–3112.
   PubMed Web of Science ®Google Scholar
• Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proceedings of the National Academy of Sciences of the United States of America.2003;100:13513–13518. doi:10.1073/pnas.2235846100.
   PubMed Web of Science ®Google Scholar
• Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005;65:967–971.
   PubMed Web of Science ®Google Scholar
• Lapteva N, Yang AG, Sanders DE, Strube RW, Chen SY. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Therapy. 2005;12:84–89. doi:10.1038/sj.cgt.7700770.
   PubMed Web of Science ®Google Scholar
• Fridlender ZG, Buchlis G, Kapoor V, Cheng G, Sun J, Singhal S, Crisanti MC, Wang LC, Heitjan D, Snyder LA, et al. CCL2 blockade augments cancer immunotherapy. Cancer Res.2010;70:109–118. doi:10.1158/0008-5472.CAN-09-2326.
   PubMed Web of Science ®Google Scholar
• Becht E, Giraldo NA, Lacroix L, Buttard B, Elarouci N, Petitprez F, Selves J, Laurent-Puig P, Sautès-Fridman C, Fridman WH, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol.2016;17:218. doi:10.1186/s13059-016-1070-5.
   PubMed Web of Science ®Google Scholar
• Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res.2009;11:R15. doi:10.1186/bcr2234.
   PubMed Web of Science ®Google Scholar
• Uddin A, Chakraborty S. Role of miRNAs in lung cancer. J Cell Physiol. 2018. doi:10.1002/jcp.26607.
   Web of Science ®Google Scholar
• Johnson E, Dickerson KL, Connolly ID, Hayden Gephart M. Single-Cell RNA-Sequencing in Glioma. Curr Oncol Rep. 2018;20:42. doi:10.1007/s11912-018-0673-2.
   PubMed Web of Science ®Google Scholar
• Schwarze SR, Luo J, Isaacs WB, Jarrard DF. Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate. 2005;64:67–74. doi:10.1002/pros.20215.
   PubMed Web of Science ®Google Scholar
• Wente MN, Mayer C, Gaida MM, Michalski CW, Giese T, Bergmann F, Giese N, Büchler MW, Friess H. CXCL14 expression and potential function in pancreatic cancer. Cancer Lett.2008;259:209–217. doi:10.1016/j.canlet.2007.10.021.
   PubMed Web of Science ®Google Scholar
• Frederick MJ, Henderson Y, Xu X, Deavers MT, Sahin AA, Wu H, Lewis DE, El-Naggar AK, Clayman GL. In vivo expression of the novel CXC chemokine BRAK in normal and cancerous human tissue. Am J Pathol.2000;156:1937–1950. doi:10.1016/S0002-9440(10)65067-5.
   PubMed Web of Science ®Google Scholar
• Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell.2004;6:17–32. doi:10.1016/j.ccr.2004.06.010.
   PubMed Web of Science ®Google Scholar
• Augsten M, Hagglof C, Olsson E, Stolz C, Tsagozis P, Levchenko T, Frederick MJ, Borg A, Micke P, Egevad L, et al. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proceedings of the National Academy of Sciences of the United States of America.2009;106:3414–3419. doi:10.1073/pnas.0813144106.
   PubMed Web of Science ®Google Scholar
• Shurin GV, Ferris RL, Tourkova IL, Perez L, Lokshin A, Balkir L, Collins B, Chatta GS, Shurin MR. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol. 2005;174:5490–5498.
   PubMed Web of Science ®Google Scholar
• Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell.2006;9:157–173. doi:10.1016/j.ccr.2006.02.019.
   PubMed Web of Science ®Google Scholar
• Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell.2013;24:331–346. doi:10.1016/j.ccr.2013.08.001.
   PubMed Web of Science ®Google Scholar
• Bijnen M, Josefs T, Cuijpers I, Maalsen CJ, Van De Gaar J, Vroomen M, Wijnands E, Rensen SS, Greve JWM, Hofker MH, et al. Adipose tissue macrophages induce hepatic neutrophil recruitment and macrophage accumulation in mice. Gut. 2018;67:1317–1327. doi:10.1136/gutjnl-2016-313654.
   PubMed Web of Science ®Google Scholar
• Lee HT, Liu SP, Lin CH, Lee SW, Hsu CY, Sytwu HK, Hsieh C-H, Shyu W-C. A Crucial Role of CXCL14 for Promoting Regulatory T Cells Activation in Stroke. Theranostics.2017;7:855–875. doi:10.7150/thno.17558.
   PubMed Web of Science ®Google Scholar
• Zhao L, Ji G, Le X, Wang C, Xu L, Feng M, Zhang Y, Yang H, Xuan Y, Yang Y, et al. Long Noncoding RNA LINC00092 Acts in Cancer-Associated Fibroblasts to Drive Glycolysis and Progression of Ovarian Cancer. Cancer Res.2017;77:1369–1382. doi:10.1158/0008-5472.CAN-16-1615.
   PubMed Web of Science ®Google Scholar
• Benarafa C, Wolf M. CXCL14: the Swiss army knife chemokine. Oncotarget. 2015;6:34065–34066. doi:10.18632/oncotarget.6040.
   PubMedGoogle Scholar
• Wang XF, Shi ZM, Wang XR, Cao L, Wang YY, Zhang JX, Yin Y, Luo H, Kang C-S, Liu N, et al. et al. MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2. J Cancer Res Clin Oncol. 2012;138:573–584. doi:10.1007/s00432-011-1114-x.
   PubMed Web of Science ®Google Scholar
• Luo H, Chen Z, Wang S, Zhang R, Qiu W, Zhao L, Peng C, Xu R, Chen W, Wang HW, et al. c-Myc-miR-29c-REV3L signalling pathway drives the acquisition of temozolomide resistance in glioblastoma. Brain: a Journal of Neurology.2015;138:3654–3672. doi:10.1093/brain/awv287.
   PubMed Web of Science ®Google Scholar